AstraZeneca Reports the P-III (I CAN) Trial Data on Ultomiris for IgA Nephropathy

Why It Matters

Reducing proteinuria is a proven surrogate for slowing IgA nephropathy progression, positioning Ultomiris as a potential first‑in‑class therapy and expanding AstraZeneca's renal portfolio.

Key Takeaways

• Ultomiris cut proteinuria by 30% at 34 weeks.
• Trial enrolled ~510 IgAN patients at progression risk.
• Early proteinuria reduction observed as soon as 10 weeks.
• eGFR outcomes to be read at week 106.
• AstraZeneca seeks accelerated approval in US, EU, Japan.

Pulse Analysis

IgA nephropathy (IgAN) affects roughly 3 million Americans and remains the leading cause of glomerular disease‑related kidney failure. Current management relies on blood‑pressure control and non‑specific immunosuppression, leaving a substantial unmet need for disease‑modifying agents. Ultomiris (ravulizumab), a long‑acting C5 complement inhibitor already approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, targets the terminal complement cascade implicated in IgAN‑driven inflammation, offering a mechanistic rationale for renal protection.

The I CAN Phase III trial randomized about 510 adults with biopsy‑confirmed IgAN and elevated risk of progression to receive intravenous Ultomiris or placebo. The interim analysis demonstrated a statistically significant 30% drop in 24‑hour urine protein‑to‑creatinine ratio at week 34, with the signal emerging by week 10. Proteinuria reduction is strongly correlated with slower decline in estimated glomerular filtration rate (eGFR), making this early efficacy signal clinically meaningful. The study’s secondary endpoint—change in eGFR—will be reported at week 106, providing a longer‑term view of renal function preservation.

AstraZeneca’s intent to seek accelerated approval in the United States, European Union, and Japan could fast‑track Ultomiris to market, tapping an estimated $1 billion IgAN therapeutic market in the U.S. alone. Success would diversify AstraZeneca’s portfolio beyond oncology and respiratory drugs, reinforcing its position in biologics. The forthcoming conference presentation will likely shape investor sentiment and set the stage for regulatory dialogues, while also prompting payers to evaluate cost‑effectiveness against existing supportive care.